Browsing: Approach

COMBINED tau biomarkers track early cognitive decline and forecast structural neurodegeneration in preclinical Alzheimer’s disease. Clinicians evaluating asymptomatic individuals with confirmed amyloid-beta deposition frequently face significant prognostic challenges due to variable disease trajectories. While plasma biomarkers offer high diagnostic sensitivity, they lack spatial precision regarding fibrillar protein localization in specific neural tissues. To address these…

Demand for GLP-1 weight loss drugs has reshaped the healthcare industry. And ETFs such as the Amplify Weight Loss Drug & Treatment ETF (THNRB-) give investors a way to access this growing market. What was once a small corner of the pharmaceutical market is now expected to become a $130 billion to $150 billion market…